IDT secures funding for new gene silencing research
02-Sep-2009
- USA
The novel mechanism utilized by the U1 adapters enable it to be used additively with existing gene technologies, or individually to target genes that have not responded well to RNAi-based techniques. The work will be performed in collaboration with Drs. Sam Gunderson and Rafal Goraczniak at SilaGene (Hillsborough, NJ), a newly formed biotechnology company working on U1 Adaptor therapeutics.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.